menu
    • menu
    [{"orgOrder":0,"company":"Joincare Pharmaceutical Group","sponsor":"TaiGen Biotechnology","pharmaFlowCategory":"D","therapeuticArea":"Infections and Infectious Diseases","country":"TAIWAN","productType":"Miscellaneous","year":"2023","type":"Licensing Agreement","leadProduct":"TG-1000","moa":"Cap-dependent endonuclease","graph1":"Infections and Infectious Diseases","graph2":"Phase III","graph3":"Joincare Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph III","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Capsule","sponsorNew":"Joincare Pharmaceutical Group \/ JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD","highestDevelopmentStatusID":"10","companyTruncated":"Joincare Pharmaceutical Group \/ JIAOZUO JOINCARE BIOTECHNOLOGICAL CO LTD"},{"orgOrder":0,"company":"Joincare Pharmaceutical Group","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Infections and Infectious Diseases","country":"CHINA","productType":"Miscellaneous","year":"2025","type":"Inapplicable","leadProduct":"JKN2501","moa":"Undisclosed","graph1":"Infections and Infectious Diseases","graph2":"Phase I","graph3":"Joincare Pharmaceutical Group","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Infectious Diseases","amount2New":0,"dosageForm":"Infusion","sponsorNew":"Joincare Pharmaceutical Group \/ Undisclosed","highestDevelopmentStatusID":"6","companyTruncated":"Joincare Pharmaceutical Group \/ Undisclosed"}]

    Find Clinical Drug Pipeline Developments & Deals by Joincare Pharmaceutical Group

    Menu

    Joincare Pharmaceutical Group

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    ACTIVE PHARMA INGREDIENTS

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Joincare Pharmaceutical Group

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Joincare Pharmaceutical Group

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : JKN2501

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Phase I Study of Single/Multiple Ascending Doses of JKN2501 for Injection in Chinese Healthy Volunteers

                            Details : JKN2501 is a small molecule drug candidate, which is currently being evaluated in Phase I clinical studies for the treatment of Bacterial Infections.

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : Inapplicable

                            October 03, 2025

                            Lead Product(s) : JKN2501

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase I

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Joincare Pharmaceutical Group

                            China arrow
                            OTS 2025
                            Not Confirmed

                            Joincare Pharmaceutical Group

                            China arrow
                            OTS 2025
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : TG-1000

                            Therapeutic Area : Infections and Infectious Diseases

                            Study Phase : Phase II

                            Recipient : TaiGen Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            DEALS_DEV arrow-down

                            TaiGen Enters Exclusive License Agreement with Joincare for TG-1000 in China

                            Details : Joincare will develop and commercialize TG-1000, a novel pan-influenza antiviral by interrupting viral replication and transmission via a cap-snatching mechanism, revealing efficacy against influenza-A, influenza-B, avian flu H7N9, and Tamiflu-resistant ...

                            Product Name : Undisclosed

                            Product Type : Miscellaneous

                            Upfront Cash : $2.9 million

                            March 22, 2023

                            Lead Product(s) : TG-1000

                            Therapeutic Area : Infections and Infectious Diseases

                            Highest Development Status : Phase II

                            Recipient : TaiGen Biotechnology

                            Deal Size : Undisclosed

                            Deal Type : Licensing Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth